| Symbol | BBOT |
|---|---|
| Name | BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | C/O CORMORANT ASSET MANAGEMENT, LP,200 CLARENDON STREET,52ND FLOOR, BOSTON, Massachusetts, 02116, United States |
| Telephone | 857 702 0377 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001869105 |
| Description | BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bbotx.com. Additional info from NASDAQ: |
New Form EFFECT - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-09-10 <b>AccNo:</b> 9999999995-26-002939 <b>Size:</b> 1 KB
Read moreNew Form EFFECT - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-09-08 <b>AccNo:</b> 9999999995-26-002909 <b>Size:</b> 1 KB
Read more(90% Positive) BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (BBOT) Announces Enrollment Update for enrolling Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreBBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
Read moreNew Form S-3 - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 0001193125-26-378637 <b>Size:</b> 1 MB
Read moreNew Form POS AM - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 0001193125-26-378366 <b>Size:</b> 984 KB
Read moreBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read more(30% Negative) BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (BBOT) Reports Q3 2026 Financial Results
Read moreBBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Read more